Discovering and developing novel treatments is only one aspect of addressing Duchenne muscular dystrophy (Duchenne) – having the capabilities to provide potential therapies to patients is just as important. Early on, we at Solid made significant investments in our gene therapy manufacturing platform to better ensure that supply would not be a barrier to delivering therapies to patients.
- Hired a highly specialized team of manufacturing process development experts
- Built a state-of-the-art process development and characterization lab
- Partnered with leading Contract Manufacturing Organizations
Through our efforts, we have developed a novel, suspension-based gene therapy manufacturing process we believe will support us through clinical trials. We believe our process can be scaled up to meet potential commercial needs should our product candidates be approved.
As our clinical program progresses, we continue to refine this process and build our team of experts with the goal of ensuring that no patient goes without therapy.